Table of Contents
✨ Onyx Summary
Affinia Therapeutics CEO Rick Modi will participate in a panel on in vivo gene therapies for genetic cardiac diseases at Chardan’s 9th Annual Genetic Medicines Conference on Oct. 21 and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference in London on Nov. 17–20.
The appearances position Affinia to highlight its AAV gene therapy pipeline in cardiovascular and neurological diseases to investors ahead of potential development milestones.
WALTHAM, Mass. – October 14, 2025 – Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced that Rick Modi, CEO, will participate at the following investor conferences in October and November. Management will also participate in one-on-one investor meetings.
Chardan’s 9th Annual Genetic Medicines Conference
Format: Panel, “In Vivo Gene Therapies for Genetic Cardiac Diseases”
Date: October 21, 2025
Time: 12:00 PM ET
Location: New York, NY
Jefferies Global Healthcare Conference – London
Format: One-on-one investor meetings
Date: November 17-20, 2025
Location: London, England
About Affinia Therapeutics
Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models. For more information, visit https://www.affiniatx.com.
Media contact:
Kathy Vincent
kathy@kathyvincent.com
310-403-8951
